EUVIMEDEUVIMED entdecken
Multizentrische Studie

Time to Positivity of a Rapid HB s A g Assay as a Surrogate Marker of Quantitative HB s A g: Multicentre Proof‐of‐Concept Study

Asegedech Asmamaw iD, Judit Romero iD, Nega Berhe iD, Mengistu Legesse, Zelalem Desalegn iD, Ariadna Rando-Segura iD, Amanda Cohn, Elena Vargas-Accarino iD, Adriana Palom iD, Juan Carlos Ruiz-Cobo iD, Mar Riveiro Barciela, Asgeir Johannessen iD und 1 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70892 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Asegedech Asmamaw und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Addis Ababa University, Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Norges Forskningsråd, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Point‐of‐care (POC) diagnostics for hepatitis B virus (HBV) are limited to qualitative results. This study evaluated whether the time to positivity of a rapid HBsAg assay could serve as a surrogate marker of quantitative HBsAg (qHBsAg) and virological activity.

Methods

This multicentre, prospective proof‐of‐concept study included cohorts from Spain and Ethiopia. Adults with chronic or resolved HBV infection and healthy controls were enrolled. Paired venous and capillary blood samples were collected; capillary blood was tested with Determine HBsAg2 rapid test recording time to positivity, while qHBsAg and HBV DNA were measured using immunoassay and PCR, respectively.

Results

A total of 513 HBsAg‐positive individuals were included (263 Spain; 250 Ethiopia). All healthy controls and individuals with resolved infection tested negative. Time to positivity showed an inverse correlation with qHBsAg in both cohorts (Spain: r = −0.749; Ethiopia: r = −0.374; p < 0.001 for both). No association was observed between time to positivity and HBV DNA levels. The performance to identify patients with HBsAg levels < 1000 IU/mL was higher in Spain (AUROC 0.86) than in Ethiopia (AUROC 0.65). Better performance was observed for detecting HBsAg levels < 100 IU/mL in both countries (AUROC 0.96 and 0.77, respectively).

Conclusions

Time to positivity in a rapid HBsAg assay correlated inversely with qHBsAg and may provide a simple, semi‐quantitative estimate of antigen burden. Although unrelated to HBV DNA, it could expand the utility of point‐of‐care HBsAg testing beyond qualitative diagnosis, particularly where quantitative HBsAg assays are unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensHepatitis B virusHepatitis B, ChronicHumansMaleAdultFemaleProspective StudiesBiomarkersEthiopiaSpainMiddle AgedDNA, ViralTime FactorsRapid Diagnostic TestsYoung AdultProof of Concept StudyPoint-of-Care SystemsImmunoassay

Stichwörter der Autor:innen

HBsAghepatitis B viruspoint‐of‐care testing

Substanzen

Hepatitis B Surface AntigensBiomarkersDNA, Viral

Autor:innen und Institutionen

  • Department of Medical Laboratory Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
  • Aklilu Lemma Institute of Health Research, Addis Ababa University, Addis Ababa, Ethiopia.
  • Research Group of Liver Diseases, Vall Hebron Research Institute, Barcelona, Spain.
  • Department of Nursing and Health, University of Barcelona, Barcelona, Spain.
  • Department of Infectious Diseases, Vestfold Hospital, Tonsberg, Norway.
  • School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

ORCID-Profile: Asegedech Asmamaw, Judit Romero, Nega Berhe, Zelalem Desalegn, Ariadna Rando-Segura, Elena Vargas-Accarino, Adriana Palom, Juan Carlos Ruiz-Cobo, Asgeir Johannessen, Maria Buti

Förderung

  • Norges Forskningsråd
  • Instituto de Salud Carlos III

Zitieren

APA

Asmamaw, A., Romero, J., Berhe, N., Legesse, M., Desalegn, Z., Rando-Segura, A., Cohn, A., Vargas-Accarino, E., Palom, A., Ruiz-Cobo, J. C., Barciela, M. R., Johannessen, A., & Buti, M. (2026). Time to Positivity of a Rapid HB s A g Assay as a Surrogate Marker of Quantitative HB s A g: Multicentre Proof‐of‐Concept Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70892

Vancouver

Asmamaw A, Romero J, Berhe N, Legesse M, Desalegn Z, Rando-Segura A, et al. Time to Positivity of a Rapid HB s A g Assay as a Surrogate Marker of Quantitative HB s A g: Multicentre Proof‐of‐Concept Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70892

BibTeX
@article{Asmamaw2026,
  author = {Asmamaw, Asegedech and Romero, Judit and Berhe, Nega and Legesse, Mengistu and Desalegn, Zelalem and Rando-Segura, Ariadna and Cohn, Amanda and Vargas-Accarino, Elena and Palom, Adriana and Ruiz-Cobo, Juan Carlos and Barciela, Mar Riveiro and Johannessen, Asgeir and Buti, Maria},
  title = {Time to Positivity of a Rapid HB s A g Assay as a Surrogate Marker of Quantitative HB s A g: Multicentre Proof‐of‐Concept Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70892}
}
Kostenlos starten →